Birth defects are common, costly and critical. Every 4½ minutes, a baby is born with a major birth defect. Professionals, community groups, and the public can act to reduce the risk of certain birth defects, detect those that occur as soon as possible and prevent secondary complications.
This issue of BDRB features a review article by Spade et al. describing the use of xenografts to study toxicity of chemicals to human fetal tissues.
The Food and Drug Administration (FDA) has announced the availability of a draft guidance for industry entitled “General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products.” Comments requested by February 9, 2015.
The US Food and Drug Administration published a Final Rule today that sets regulations for how information about using medicines during pregnancy and breastfeeding is presented in the labeling of prescription drugs and biological products.
Special Issue: NBDPN CDC order – National Birth Defects Prevention Network